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Dear Editor,
The  emergence of ertapenem resistance in Klebsiella pneu-
moniae,  related to the production of carbapenemases such
as  KPC enzymes is worrisome because it decreases cur-
rent  antimicrobial drugs available for the treatment of
these  microorganisms. In Colombia KPC-2 producing orga-
nisms  have been reported and are frequently resistant
to  multiple plasmid-mediated antibiotic classes.1 Thirteen
broad-spectrum cephalosporins-resistant isolates of the fam-
ily Enterobacteriaceae (11 K. pneumoniae and 2 Escherichia coli)
were  collected from two private tertiary care clinics in
Villavicencio between October 2008 and September 2009.
The  isolates were  screened by PCR assay for blaTEM, -SHV,
-CTX-M-1, -CTX-M-2, -CTX-M-8, -CTX-M-9, -PER-2, -CMY-2 and blaKPC
genes. Sequencing of the ampliﬁed fragments identiﬁed
CTX-M-12 (13/13) as the most frequent enzyme in the clin-
ical  isolates evaluated, followed by SHV-12 (7/13), TEM-1
(4/13),  KPC-2 (3/13), CTX-M-8 (1/13), and SHV-5 (1/13). One
of  the 11 K. pneumoniae isolates carried two CTX-M type
genes  and one SHV-type gene concomitantly. Three KPC-
producer  K. pneumoniae isolates also encoded for expression
of  blaCTX-M-12 gene and blaSHV-12 concomitantly. Two E. coli
isolates were  carrying blaCTX-M1 like gene. The combination
of two CTX-M type genes found in one isolate of K. pneumo-
niae  is of interest because the blaCTX-M-8 gene is commonly
plasmid-harbored and does not show resistance to non--
lactams  antibiotics (aminoglycosides, ﬂuoroquinolones and
trimethoprim-sulfamethoxazole). These resistance genes are
encoded by plasmid, with the exception of tetracycline that
expressed  resistance with MICs of >8 mg/L. The nucleotide
sequencing of three isolates positive for KPC genes showed
100%  blaKPC-2 (accession number AY034847) similarity. The
fact  that some K. pneumoniae isolates harbor multiple ESBL
genes  in combination with the carbapenemase KPC-2 encod-
ing  gene is important as this isolates were  susceptible in vitro
to  all carbapenems with Microscan Neg Combo Panel Type 50
(Dade  Behring, CA, USA). Susceptibility interpreted according
to  CLSI standards2 could increase the likelihood of thera-
peutic  failures whether ertapenem is used to treat urinary
tract  infections or blood stream infections because in vivoio,  Colombia
carbapenemase could hydrolyze ertapenem.3,4 Although
reported ertapenem susceptibility could in fact be false sus-
ceptibility  because of the higher breakpoint at MicroScan
panel type 50 systems. The use of other panels like MicroScan
urinary  reference could prevent unnecessary reporting of false
negative  results by using lower breakpoints according to CLSI
standards.  Despite ertapenem resistance carbapenems, such
as  doripenem, have been proposed to treat infections caused
by  KPC-producing isolates for its ability to achieve bacterio-
static  activity.5 The PFGE of ESBL-producing K. pneumoniae
isolates showed two clusters of 84% and 94% similarity, respec-
tively.  Isolates from cluster 1 expressed ESBL type CTX-M-12
and  KPC-2, and cluster 2 isolates expressed ESBL type CTX-
M-12,  SHV-12 and KPC-2. Antimicrobial phenotype for cluster
1  isolates expressed resistance to non--lactam antibiotics,
i.e.,  to almost all aminoglycosides (MICs for gentamicin of
≥8  mg/L), ﬂuoroquinolones (MICs of ciproﬂoxacin >2 mg/L),
and  the combination of sulfamethoxazole and trimethoprim.
The  exception was  tetracycline that showed susceptibility,
MICs <4 mg/L. Cluster 2 isolates expressed resistance to all
non--lactam  antibiotics. Emergence KPC enzymes is worri-
some  due to therapeutic failures when ertapenem is used.
However,  possible false susceptibility results to ertapenem
can  occur in clinical microbiology laboratories when reference
breakpoints from automated systems, such as MicroScan, are
used.
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